Mizuho Markets Americas LLC Increases Holdings in Halozyme Therapeutics, Inc. $HALO

Posted by Francis Steltz on May 23rd, 2026

Mizuho Markets Americas LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 270.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,268,673 shares of the biopharmaceutical company’s stock after purchasing an additional 926,526 shares during the quarter. Halozyme Therapeutics accounts for approximately 1.6% of Mizuho Markets Americas LLC’s investment portfolio, making the stock its 13th largest holding. Mizuho Markets Americas LLC’s holdings in Halozyme Therapeutics were worth $85,382,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of HALO. Root Financial Partners LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $25,000. Larson Financial Group LLC lifted its stake in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the period. Clearstead Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 265 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $52,000. Finally, Wexford Capital LP acquired a new stake in shares of Halozyme Therapeutics in the third quarter worth $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. HC Wainwright increased their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Benchmark boosted their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $80.67.

Read Our Latest Analysis on HALO

Insider Activity

In related news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the sale, the director owned 38,498 shares of the company’s stock, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at approximately $477,200.20. The trade was a 55.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 120,482 shares of company stock worth $8,200,842 over the last three months. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Down 0.3%

Shares of HALO opened at $68.32 on Friday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22. The stock has a market capitalization of $8.10 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 0.28 and a beta of 0.89. The stock has a 50 day moving average price of $65.74 and a 200 day moving average price of $68.75.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the firm posted $1.11 EPS. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.